Command Hospital (Eastern Command), Kolkata administered NexCAR19, India's first indigenous CAR-T cell therapy, to a 39-year-old serving soldier; the Army's Eastern Command announced it on 5 October 2026
The soldier has relapsed/refractory B-cell Acute Lymphoblastic Leukaemia (B-cell ALL), a blood cancer
NexCAR19 was developed by IIT Bombay, the Tata Memorial Centre and the start-up ImmunoACT; it targets the CD19 protein on B cells
Command Hospital (Western Command), Chandimandir gave its first CAR-T therapy, to a 16-year-old, in September 2026
Chimeric Antigen Receptor T-cell therapy is an immunotherapy. A patient's own T cells are collected, genetically modified to carry a receptor that recognises a marker on cancer cells, multiplied in a laboratory and infused back to hunt those cells.
Simple Analogy: Like taking the body's own guards out, training them to spot one enemy badge, and sending them back.
US FDA approves Kymriah (tisagenlecleucel), the first CAR-T cell therapy in the world
CDSCO approves NexCAR19, India's first CAR-T therapy
President Droupadi Murmu dedicates NexCAR19 to the nation at IIT Bombay
Army announces Command Hospital (Western Command), Chandimandir's first CAR-T therapy, for a 16-year-old with B-cell ALL; it is the first Command Hospital after Army Hospital (R&R), Delhi to offer it
Eastern Command announces the therapy for a 39-year-old serving soldier at Command Hospital, Kolkata
Tertiary-care hospital of the Armed Forces Medical Services for the Army's Eastern Command
Armed forces hospital that gave its first CAR-T therapy in September 2026
Biotechnology start-up incubated at IIT Bombay that makes NexCAR19
Cancer institute under the Department of Atomic Energy; clinical partner for NexCAR19
National drug regulator under the Ministry of Health and Family Welfare; approved NexCAR19 in 2023
GS Paper 3 > Science and Technology > Biotechnology; indigenisation of technology
General Awareness > Science and Technology in news
Chimeric Antigen Receptor T-cell therapy: a patient's T cells are engineered to recognise and kill cancer cells
A protein on the surface of B cells; the marker NexCAR19 is built to find
Relapsed: the cancer has returned after treatment. Refractory: it did not respond adequately to treatment